ATAPAC Study (TauroLock Activity in Adult Cancer Patients)

Launched by CENTRE HOSPITALIER RÉGIONAL METZ-THIONVILLE · Oct 29, 2014

Keywords

ClinConnect Summary

The central venous catheter (CVC)-associated bloodstream infection (CLABSI) represent a serious and persistent health problem in cancer patients with an implantable CVC receiving an intravenous (IV) anti-tumor therapy. The CLABSI include the CVC-associated bacteremia and the negative bloodstream local or generalized infections. CLABSI significantly increase morbidity and hospital costs. They can lead also to discontinuation of IV anti-tumor treatment, a severe sepsis, a septic shock or a death. Microbial colonization and biofilm development, which are resistant to antibiotic therapy, often ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients older than 18 years
• • Performance Index (WHO score) ≤ 2
• • Patient with a solid cancer receiving an IV anti-tumor treatment
• • Presence of a totally implantable CVC
• • Anti-tumoral therapy administered by a totally implantable CVC
• • Metastatic and / or (neo) adjuvant treatment
• • Full hospitalised and / or day-hospital patients
• • Informed written consent
• • Social Health security insurance
• Exclusion Criteria:
• • Hematological cancer patients
• • HIV-positive patients and/ or patients receiving an active immunosuppressive therapy
• • Patients presenting a febrile episode within 4 days prior to randomisation
• • Patients with neutropenia grade ≥ 2 (ANC ≤ 1000/mm3) on a blood testing older than 7 days
• • Patients on IV antibiotic therapy
• • Patients on total and / or peripheral parental nutrition
• • Patients with a previous CLABSI history
• • Allergy to citrate or taurolidine
• • Patients who are not able to give an informed consent
• • Patients under guardianship
• • Patients under judicial protection
• • Pregnant or breastfeeding woman